Clinical Trial Update: A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Sacituzumab Govitecan (IMMU-132) in patients with recurrent or persistent cervical cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• TRODELVY (sacituzumab govitecan)

Snippet

Sponsor: Yale University | Conditions: Cervical Cancer | Phase 2 | Status: RECRUITING